ABSTRACT

The present investigation was to create and approve another reverse phase fluid chromatographic (RP-HPLC) strategy to measure in vitro examine of risperidone in drug tablet dose structure. The separation was performed on Inertsil ODS C-18 (150 x 4.6 mm, 5?) molecule size section, and infusion volume was 10?L utilizing a UV 2301 Spectrophotometer to screen the identification at 260 nm. The mobile phase comprised of methanol: 0.1% formic acid in the proportion 40:60%v/v, and the stream rate was kept up at 1.0 ml/min. the technique was approved as far as reasonableness, linearity, exactness, accuracy, solidness, and affectability. Linearity was seen over the scope of focus 4.0-12.0?g/ml, and the correlation coefficient was found phenomenal >0.9999. The technique was exact and had relative standard deviations (%RSD) under 2.0%. Exactness was found in the scope of 99.90 to 101.7%.The developed procedure was vigorous in various variable conditions and reproducible. This proposed technique can be utilized as quality control device for the assessment of risperidone in routine disintegration test investigation. Keywords: Risperidone, RP-HPLC, Validation
Publication date: 01/12/2021

https://ijbpas.com/pdf/2021/December/MS_IJBPAS_2021_DEC_SPCL_2008.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.12.2008